Mauna Kea Technologies SAS (ALMKT) - Net Assets

Latest as of June 2025: €-29.42 Million EUR ≈ $-34.40 Million USD

Based on the latest financial reports, Mauna Kea Technologies SAS (ALMKT) has net assets worth €-29.42 Million EUR (≈ $-34.40 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€12.66 Million ≈ $14.80 Million USD) and total liabilities (€42.08 Million ≈ $49.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Mauna Kea Technologies SAS (ALMKT) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets €-29.42 Million
% of Total Assets -232.39%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change -273.08%
Growth Volatility 1369.25

Mauna Kea Technologies SAS - Net Assets Trend (2008–2024)

This chart illustrates how Mauna Kea Technologies SAS's net assets have evolved over time, based on quarterly financial data. Also explore Mauna Kea Technologies SAS (ALMKT) total assets for the complete picture of this company's asset base.

Annual Net Assets for Mauna Kea Technologies SAS (2008–2024)

The table below shows the annual net assets of Mauna Kea Technologies SAS from 2008 to 2024. For live valuation and market cap data, see ALMKT market cap overview.

Year Net Assets Change
2024-12-31 €-24.39 Million
≈ $-28.51 Million
-41.17%
2023-12-31 €-17.28 Million
≈ $-20.20 Million
+13.29%
2022-12-31 €-19.93 Million
≈ $-23.29 Million
-92.83%
2021-12-31 €-10.33 Million
≈ $-12.08 Million
+14.44%
2020-12-31 €-12.08 Million
≈ $-14.12 Million
-4873.52%
2019-12-31 €253.00K
≈ $295.78K
-96.83%
2018-12-31 €7.98 Million
≈ $9.33 Million
-52.35%
2017-12-31 €16.74 Million
≈ $19.58 Million
+50.08%
2016-12-31 €11.16 Million
≈ $13.04 Million
-20.82%
2015-12-31 €14.09 Million
≈ $16.47 Million
-22.36%
2014-12-31 €18.15 Million
≈ $21.22 Million
-39.82%
2013-12-31 €30.16 Million
≈ $35.26 Million
-24.91%
2012-12-31 €40.16 Million
≈ $46.95 Million
-22.13%
2011-12-31 €51.57 Million
≈ $60.30 Million
+651.57%
2010-12-31 €6.86 Million
≈ $8.02 Million
-34.11%
2009-12-31 €10.41 Million
≈ $12.18 Million
-28.68%
2008-12-31 €14.60 Million
≈ $17.07 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Mauna Kea Technologies SAS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1040400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock €2.71 Million %
Other Comprehensive Income €-26.16 Million %
Other Components €9.46 Million %
Total Equity €-24.39 Million 100.00%

Mauna Kea Technologies SAS Competitors by Market Cap

The table below lists competitors of Mauna Kea Technologies SAS ranked by their market capitalization.

Company Market Cap
Kincora Copper Ltd
AU:KCC
$28.44 Million
ContextVision AB
OL:CONTX
$28.45 Million
Chien Wei Precise Technology Co Ltd
TWO:8092
$28.46 Million
EMB Mission Bound AB (publ)
ST:NAVIGO-STAM
$28.48 Million
C-Com Satellite Systems Inc.
V:CMI
$28.43 Million
Okong Corporation
KQ:045060
$28.42 Million
TOUAX
PA:ALTOU
$28.40 Million
Desoto Resources Ltd
AU:DES
$28.40 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Mauna Kea Technologies SAS's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from -17,277,000 to -24,389,000, a change of -7,112,000.
  • Net loss of 10,404,000 reduced equity.
  • Share repurchases of 2,088,000 reduced equity.
  • New share issuances of 2,088,000 increased equity.
  • Other comprehensive income decreased equity by 2,545,000.
  • Other factors increased equity by 5,837,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income €-10.40 Million -42.66%
Share Repurchases €2.09 Million -8.56%
Share Issuances €2.09 Million +8.56%
Other Comprehensive Income €-2.54 Million -10.44%
Other Changes €5.84 Million +23.93%
Total Change €- %

Book Value vs Market Value Analysis

This analysis compares Mauna Kea Technologies SAS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2010-12-31 €0.16 €0.18 x
2011-12-31 €4.38 €0.18 x
2012-12-31 €2.99 €0.18 x
2013-12-31 €2.20 €0.18 x
2014-12-31 €1.31 €0.18 x
2015-12-31 €0.84 €0.18 x
2016-12-31 €0.54 €0.18 x
2017-12-31 €0.69 €0.18 x
2018-12-31 €0.29 €0.18 x
2019-12-31 €0.01 €0.18 x
2020-12-31 €-0.34 €0.18 x
2021-12-31 €-0.23 €0.18 x
2022-12-31 €-0.38 €0.18 x
2023-12-31 €-0.35 €0.18 x
2024-12-31 €-0.35 €0.18 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Mauna Kea Technologies SAS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -135.91%
  • • Asset Turnover: 0.47x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-444.01%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2010 -56.73% -96.12% 0.34x 1.74x €-4.58 Million
2011 -15.38% -158.19% 0.08x 1.17x €-13.09 Million
2012 -32.51% -148.20% 0.18x 1.22x €-17.07 Million
2013 -38.18% -115.43% 0.25x 1.31x €-14.53 Million
2014 -77.09% -127.01% 0.40x 1.52x €-15.81 Million
2015 -89.72% -147.92% 0.38x 1.60x €-14.05 Million
2016 -87.34% -110.89% 0.44x 1.79x €-10.86 Million
2017 -61.19% -153.21% 0.24x 1.66x €-11.92 Million
2018 -165.67% -195.52% 0.34x 2.48x €-14.01 Million
2019 -6036.36% -179.48% 0.36x 93.36x €-15.30 Million
2020 0.00% -196.00% 0.32x 0.00x €-11.58 Million
2021 0.00% -174.61% 0.31x 0.00x €-12.41 Million
2022 0.00% -149.49% 0.38x 0.00x €-9.19 Million
2023 0.00% -33.80% 0.48x 0.00x €-2.00 Million
2024 0.00% -135.91% 0.47x 0.00x €-7.97 Million

Industry Comparison

This section compares Mauna Kea Technologies SAS's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $35,306,105
  • Average return on equity (ROE) among peers: -14.65%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Mauna Kea Technologies SAS (ALMKT) €-29.42 Million -56.73% N/A $28.43 Million
Affluent Medical SAS (AFME) $43.53 Million -34.04% 0.61x $110.43 Million
Biosynex (ALBIO) $66.29 Million 47.32% 0.90x $15.74 Million
Bluelinea SA (ALBLU) $1.41 Million -89.92% 5.64x $9.16 Million
Carmat (ALCAR) $-43.76 Million 0.00% 0.00x $6.37 Million
Diagnostic Medical Systems SA (ALDMS) $23.35 Million -3.64% 0.72x $34.50 Million
Eurobio Scientific SA (ALERS) $175.17 Million 2.76% 0.81x $236.10 Million
Ikonisys SA (ALIKO) $6.09 Million -30.86% 0.34x $21.30 Million
Implanet SA (ALIMP) $6.93 Million 0.00% 0.70x $32.93 Million
Mediantechn (ALMDT) $38.74 Million -23.52% 0.20x $200.33 Million

About Mauna Kea Technologies SAS

PA:ALMKT France Medical Devices
Market Cap
$41.32 Million
€35.35 Million EUR
Market Cap Rank
#23875 Global
#387 in France
Share Price
€0.18
Change (1 day)
+0.11%
52-Week Range
€0.07 - €0.22
All Time High
€5.37
About

Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate… Read more